Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental practices using tocilizumab-aazg for autoimmune patients risk contamination if they stock or administer recalled Tyenne vials; owners and staff must verify inventory to avoid potential particulate-related adverse events.
Key points
- Fresenius Kabi is recalling one lot of Tyenne (tocilizumab-aazg) 400 mg/20 mL vials nationwide due to glass particulate contamination.
- The affected product is for intravenous administration, primarily used in rheumatology and immunology; dental clinics with in-office infusions or shared specialty medication stock should quarantine the lot.
- No dental-specific devices or local anesthetics are involved; the recall targets a systemic biologic used for conditions such as rheumatoid arthritis that some dental patients may receive.
- Action: check lot numbers against the August 10, 2026 recall notice, segregate affected stock, and coordinate returns through Fresenius Kabi or your wholesaler.
Who should care
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.
Related
- ·Business
Why the dental assistant shortage could get worse
- ·Business
US Oral Surgery Management exec on M&A: ‘We’ve had to be even more disciplined’
- ·Research
Vertical dimension of occlusion restoration using a digital injectable composite resin technique: A 5-year clinical follow-up
- ·Research
A digitally guided workflow integrating tooth preparation and restoration positioning for minimally invasive veneer and partial-coverage restorations: A dental technique